Microcap Healthcare Stocks to Watch: STRR, WHSI, MOTS, ATOS, ADMP

January 21, 2022

The following stocks hit our radar when searching for microcap opportunities in the healthcare sector.  This particular segment of the market is ripe for opportunity when considering speculative investments.  Most of the companies are in early trial stages without any revenue, however, what they lack in revenue they make up for in potential and that’s what moves these markets. One nano-cap option on the OTC in this sector, Wearable Health…

Read More >>

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Stock Falls Again: Now Down 25% in a Month

November 24, 2021

The Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) stock was in the middle of a selloff on Tuesday as investors headed for the exits and ended the day with a decline of as much as 8.50%. Trading Data On Tuesday, ADMP stock slumped 8.35% at $0.81 with more than 4.96 million shares, compared to its average volume of 6.11 million shares. The stock has moved within a range of $0.7500 – 0.8500 after…

Read More >>

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Stock Moves Up Again: Jumps 16% in a Week

October 19, 2021

Yesterday, Adamis Pharmaceuticals Corp (NASDAQ:ADMP) was in the news after the company announced that its product Zimhi was approved by the United States Food and Drug Administration. It goes without saying that it was a major development for the company and the Adamis stock ended the day with gains of 8%. It should be noted at the same time that the Adamis stock is up by as much as 16%…

Read More >>

ADAMIS Pharmaceuticals Corporation (NASDAQ:ADMP) Stock Continues to Gain Momentum: Now What?

September 7, 2021

ADAMIS Pharmaceuticals Corporation (NASDAQ:ADMP) is up 8% in a month. Recently the company received a notice from The Nasdaq Stock Market LLC’s Listing Qualification Department regarding its failure to file its Quarterly Reports on Form 10-Q for the quarter ending June 30, 2021, as well as for the quarter ended March 31, 2021. As a result of the failure, the company is not compliant with listing Marketplace Rule 5250(c)(1). The…

Read More >>

Adamis Pharmaceuticals Corporation (ADMP) Stock Moves Up After The Key clinical study

September 3, 2021

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) jumped 3% after announcing patient dosing commencement in its Phase 2/3 clinical study for Tempol. Tempol is an oral antiviral treatment the company is developing to treat adult patients with COVID-19 infection. The antiviral product has demonstrated in preclinical studies that it has antioxidant, anti-inflammatory, and antiviral activity. Adamis is expected to recruit 248 patients in the study. Principal study investigator ShyamKottilil said that the timing…

Read More >>